- Email: [email protected]
Prospective Evaluation of Glucose Tolerance and Insulin Resistance Among Patients with Endometrial Cancer and Atypical Endometrial Hyperplasia
Annals of Oncology 25 (Supplement 4): iv305–iv326, 2014 doi:10.1093/annonc/mdu338.52
gynaecological cancers
928P
A. Mitsuhashi, S. Hanawa, N. Yamamoto, T. Uehara, K. Nishikimi, S. Tate, H. Usui, M. Shozu Reproductive Medicine, Graduate School of Medicine, Chiba University, Chiba, JAPAN
abstracts
Aim: Obesity and diabetes mellitus (DM) increase the risk of endometrial cancer (EC). However, the prevalence of insulin resistance (IR) and DM, including pre-DM, among Japanese patients with EC remains unclear. This study aimed to evaluate the prevalence of IR and DM, including pre-DM, among Japanese patients with EC, as well as their associations with clinical characteristics. Methods: We prospectively enrolled patients with atypical endometrial hyperplasia (AEH) and EC who received planned treatment at Chiba University Hospital. All patients, except those with a confirmed diagnosis of DM, underwent the 75-g oral glucose tolerance test (OGTT) before treatment. IR was defined as a history of
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_4/iv321/2241645 by guest on 27 October 2019
PROSPECTIVE EVALUATION OF GLUCOSE TOLERANCE AND INSULIN RESISTANCE AMONG PATIENTS WITH ENDOMETRIAL CANCER AND ATYPICAL ENDOMETRIAL HYPERPLASIA
DM or a homeostasis model assessment of insulin resistance score ≥ 2.5. We compared the metabolic status of patients with type I (AEH, and endometrioid grade 1 and grade 2) and type II (endometrioid grade 3, serous carcinoma, and clear cell carcinoma) patients as well as premenopausal and postmenopausal patients. Results: We enrolled 216 patients from March 2009 to February 2014. Among these 216 patients, 36 had a confirmed diagnosis of DM. Other than these 36 patients, abnormal OGTT results were noted in 85 patients. IR was observed in 47% of patients. A total of 161 patients (75%) had risk factors of EC such as DM/pre-DM, IR or obesity. Premenopausal patients were more frequently obese and more frequently exhibited IR than postmenopausal patients (68% versus 40%, p < 0.01; 57% versus 40%, p = 0.014). Postmenopausal patients exhibited DM and abnormal OGTT results more often than premenopausal patients; however, this difference was not statistically significant (61% versus 49%, p = 0.098). Type I EC patients were more frequently obese and more frequently exhibited IR than type II EC patients (58% versus 27%, p < 0.001; 51% versus 31%, p = 0.033). Type I EC patients exhibited DM and abnormal OGTT results less frequently than type II EC patients; however, this difference was not statistically significant (53% versus 69%, p = 0.076). Conclusions: DM, including pre-DM, IR, and obesity were found to be highly prevalent in patients with EC and AEH. These results may support that the management of metabolic status is important for improving the survival of these patients. Disclosure: All authors have declared no conflicts of interest.
© European Society for Medical Oncology 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
gynaecological cancers
928P
A. Mitsuhashi, S. Hanawa, N. Yamamoto, T. Uehara, K. Nishikimi, S. Tate, H. Usui, M. Shozu Reproductive Medicine, Graduate School of Medicine, Chiba University, Chiba, JAPAN
abstracts
Aim: Obesity and diabetes mellitus (DM) increase the risk of endometrial cancer (EC). However, the prevalence of insulin resistance (IR) and DM, including pre-DM, among Japanese patients with EC remains unclear. This study aimed to evaluate the prevalence of IR and DM, including pre-DM, among Japanese patients with EC, as well as their associations with clinical characteristics. Methods: We prospectively enrolled patients with atypical endometrial hyperplasia (AEH) and EC who received planned treatment at Chiba University Hospital. All patients, except those with a confirmed diagnosis of DM, underwent the 75-g oral glucose tolerance test (OGTT) before treatment. IR was defined as a history of
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_4/iv321/2241645 by guest on 27 October 2019
PROSPECTIVE EVALUATION OF GLUCOSE TOLERANCE AND INSULIN RESISTANCE AMONG PATIENTS WITH ENDOMETRIAL CANCER AND ATYPICAL ENDOMETRIAL HYPERPLASIA
DM or a homeostasis model assessment of insulin resistance score ≥ 2.5. We compared the metabolic status of patients with type I (AEH, and endometrioid grade 1 and grade 2) and type II (endometrioid grade 3, serous carcinoma, and clear cell carcinoma) patients as well as premenopausal and postmenopausal patients. Results: We enrolled 216 patients from March 2009 to February 2014. Among these 216 patients, 36 had a confirmed diagnosis of DM. Other than these 36 patients, abnormal OGTT results were noted in 85 patients. IR was observed in 47% of patients. A total of 161 patients (75%) had risk factors of EC such as DM/pre-DM, IR or obesity. Premenopausal patients were more frequently obese and more frequently exhibited IR than postmenopausal patients (68% versus 40%, p < 0.01; 57% versus 40%, p = 0.014). Postmenopausal patients exhibited DM and abnormal OGTT results more often than premenopausal patients; however, this difference was not statistically significant (61% versus 49%, p = 0.098). Type I EC patients were more frequently obese and more frequently exhibited IR than type II EC patients (58% versus 27%, p < 0.001; 51% versus 31%, p = 0.033). Type I EC patients exhibited DM and abnormal OGTT results less frequently than type II EC patients; however, this difference was not statistically significant (53% versus 69%, p = 0.076). Conclusions: DM, including pre-DM, IR, and obesity were found to be highly prevalent in patients with EC and AEH. These results may support that the management of metabolic status is important for improving the survival of these patients. Disclosure: All authors have declared no conflicts of interest.
© European Society for Medical Oncology 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].